MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.carrev.2026.10.006

Медицинская библиотека · Cardiovascular revascularization medicine : including molecular interventions · 2026

Short-frame, self-expanding, fully recapturable transcatheter aortic valve replacement device in pure aortic regurgitation: Procedural performance and 30-day outcomes.

Yan Hui, Li Yunyao, Wan Weiguo, Liao Haihan, Cao Sheng, Song Hongning, Zhou Xiaoya, Jiang Hong, Huang Bing

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Achieving stable anchoring and effective sealing remains the principal limitation of transcatheter aortic valve replacement (TAVR) in patients with pure native aortic regurgitation (PNAR). A short-frame, fully recapturable self-expanding valve may expand the procedural margin by enabling iterative repositioning and implantation depth optimisation in non-calcified anatomy.

METHODS

We analysed 13 consecutive patients with symptomatic moderate-to-severe or severe PNAR who underwent transfemoral TAVR with the ScienCrown® (Lepu Medical, Beijing, China) system. The primary endpoint was technical success at exit from the procedure room according to VARC-3 criteria. Secondary endpoints included device success and early safety at 30 days.

RESULTS

Technical success was achieved in all patients (13/13, 100%), and device success at 30 days was also achieved in all patients (13/13, 100%). The 30-day early safety endpoint was met in 12 patients (92.3%). The mean prosthesis size was 27.62 ± 1.26 mm, with a mean prosthesis diameter oversizing relative to the average annular diameter of 12.90 ± 3.54%; no balloon predilatation was performed. The mean number of deployment attempts was 1.62 ± 0.77. All procedures were completed without valve embolisation/migration, coronary obstruction, second-valve implantation, or emergency surgery. One patient (7.69%) developed complete atrioventricular block on postoperative day 3 and underwent permanent pacemaker implantation; no additional pacemaker implantations occurred through 30 days. Predischarge diffusion-weighted magnetic resonance imaging demonstrated no new acute cerebral infarction. At 30 days, there were no deaths, strokes or transient ischaemic attacks, myocardial infarction, life-threatening/major bleeding, major vascular complications, endocarditis, or valve-related reinterventions. Mean transvalvular gradients were 7.67 ± 5.20 mmHg, and all patients had improved or stable NYHA functional class with no moderate or severe residual aortic regurgitation.

CONCLUSIONS

In this exploratory single-centre series, transfemoral TAVR using a short-frame, fully recapturable self-expanding valve achieved 100% technical success and favourable early safety and haemodynamic performance in selected patients with PNAR. Prospective multicentre studies with longer follow-up and appropriate comparator groups are warranted.

Для цитирования: Yan Hui, Li Yunyao, Wan Weiguo, Liao Haihan, Cao Sheng, Song Hongning, Zhou Xiaoya, Jiang Hong, Huang Bing. Short-frame, self-expanding, fully recapturable transcatheter aortic valve replacement device in pure aortic regurgitation: Procedural performance and 30-day outcomes.. Cardiovascular revascularization medicine : including molecular interventions. 2026. DOI: 10.1016/j.carrev.2026.10.006.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.